WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical ...

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today reported ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate ...

Full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million. Optune Lua® received FDA approval for the treatment of metastatic non-small cell lung ...

THE US headquartered clinical research firm Celerion has announced it will relocate its Belfast operation to the new Queen’s ...

Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment ...

Bayer presents positive results from phase III study QUANTI CNS of gadoquatrane at ECR 2025: Berlin Thursday, February 27, 2025, 14:00 Hrs [IST] Bayer, a global leader in radiolog ...

STOCKHOLM, SWEDEN / ACCESS Newswire / February 27, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its Year-end report for the period Januar ...

Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET. Company Participants. Katie Hogan - Senior Director-Corporate Communications and Investo ...

The partnership focuses on radioligand therapy, cell therapy, and early-phase trials. Singapore General Hospital (SGH) and ...

Five years later, and in the face of a potentially changing healthcare landscape again, Dr. Lynch is ever committed and steadfast in his vision for the NCI-designated cancer center. He recently shared ...